Discover
HemeTalks: Conversations in Hematology Education
HemeTalks: Conversations in Hematology Education
Author: American Society of Hematology
Subscribed: 56Played: 327Subscribe
Share
© 2026 American Society of Hematology
Description
HemeTalks: Conversations in Hematology Education is an American Society of Hematology (ASH) podcast for community hematologists, advanced practice providers, and trainees. Through engaging storytelling and case-based discussions with guests ranging from early-career professionals to leading experts, the podcast offers practical strategies that make complex hematology topics accessible and relevant at every career stage. Its mission is to support the educational needs of its audience through high-quality, clinically focused content.
46 Episodes
Reverse
In this episode of HemeTalks: Conversations in Hematology, hosts Dr. Ronak Mistry and Dr. Vivek Patel are joined by Dr. Enrico Novelli, Professor of Medicine at the University of Maryland and leader of its sickle cell disease program, for a deep dive into the biology and management of sickle cell disease. Dr. Novelli unpacks molecular pathways beyond vaso-occlusion, including hyper-adhesion, oxidative stress, and hemolysis, that drive disease complications and are opening the door to new therapeutic targets. The conversation covers why hydroxyurea remains the treatment backbone despite being underutilized, the challenges of designing clinical trials with meaningful endpoints, and when to reach for exchange transfusion in both acute and chronic settings. A must-listen for anyone caring for patients with sickle cell disease.Clinical Pearls:Hydroxyurea is an underutilized but critical backbone of therapy for treating patients with sickle cell disease.Clinical trials for sickle cell disease need better, more diverse clinical endpoints.Limited options are currently available on the market for the management of sickle cell disease. Options include crizanlizumab and L-glutamine. Mitapivat is currently pending approval. Curative options, including stem cell transplant and gene therapy, are also available, but selecting the appropriate therapy is now the challenge.Exchange transfusions remain a powerful tool. Consider them in the acute setting for patients needing a higher level of care and in the outpatient setting for patients with complications of disease despite maximal doses of agents, such as hydroxyurea.Trust-based, longitudinal care is central to high-quality sickle cell disease care.This episode was supported by Sanofi.
In this patient advocate episode, Ms. Barbara Pruitt shares what it's like to live with immune thrombocytopenia (ITP), a condition she has had since age four. Barbara takes us through more than six decades of treatments, from childhood steroids and a splenectomy to today's newer therapies. She describes growing up without meeting anyone else with ITP and the moment a patient organization changed that. She also talks about the everyday adjustments that let her keep traveling, dancing, and enjoying life, and how a hematologist's words can either wound or empower. Hosts Drs. Ronak Mistry and Vivek Patel explore what clinicians can learn from her story, including why quality of life matters as much as lab values. Barbara closes with advice for anyone newly diagnosed.Key Takeaways:Treat the diagnosis as an emotional event, not just a clinical one. Barbara reminds physicians to acknowledge the emotional weight of the diagnosis, and connect patients to peer communities and support resources early, especially children and teens. Look beyond the platelet count. Barbara's current therapy hasn't raised her count, but less bruising and fewer petechiae make it worth continuing. She urges clinicians not to abandon a therapy over a small fluctuation and encourages listeners to ask about other symptoms of ITP including fatigue, bleeding, and energy, which are often dismissed. Ask about symptoms and function at every visit, and weigh them alongside the number when judging whether a treatment is working. Plan the treatment around the patient's life.Consider how treatment options impact our patient’s quality of life. Present all reasonable options with their pros and cons, and think through practical fit, such as injections versus oral drugs and food interactions. Invite questions about activities and alternative therapies, because patients will otherwise go looking on their own. For additional ASH resources related to ITP, please consider visiting our ASH Clinical Practice Guidelines on Immune Thrombocytopenia web page.This episode was supported by Sanofi.
In this episode of HemeTalks, we are joined by Ms. Elise Burton, who shares her experience living with paroxysmal nocturnal hemoglobinuria (PNH). Elise describes how her journey began several years earlier with a diagnosis of aplastic anemia, before her condition was later recognized as PNH after she developed evidence of unexplained hemolysis. She walks through her treatment journey, including eculizumab, ravulizumab, and enrollment in a danicopan clinical trial, as well as the side effects she experienced, the financial navigation required to stay on therapy, and the routine health maintenance that can be displaced when managing a rare disease becomes all-consuming. She also discusses the patient communities and advocacy organizations that supported her. Our patient advocate episodes highlight the importance of advocacy, community, and shared understanding between patients and their health care providers. Key Takeaways:1. Preemptive anticipatory counseling is critical for patients, particularly those with rare diseases, to ensure rapid access to life-saving care in emergencies. Elise shares how her hematologist made sure she understood her condition and gave her essential contact information, along with a letter detailing her condition to share with healthcare professionals if she ever needed emergency medical attention. Equipping patients with a plan before a crisis can meaningfully change the care they receive.2. Rare disease care can become a part-time job, and general health maintenance can get lost. Patients with chronic hematologic diseases have medical needs beyond their hematologic condition. Hematologists can help by acknowledging the administrative burden, connecting patients with organizations such as AAMDS, NORD, The Assistance Fund, and the Patient Advocate Foundation, and reinforcing the importance of routine health screenings.To access the PNH patient resources mentioned in this episode, please refer to the link provided here.This episode was supported by Alexion.
Dr. Cece Calhoun (Yale School of Medicine) joins Heme Talks to discuss one of the most vulnerable moments in sickle cell care: the transition from pediatric to adult management. Using a real case of a 24-year-old with hemoglobin SC disease re-establishing care after a lapse, Dr. Calhoun walks through how to build trust with adolescent and young adult patients, why sickle cell disease is a systemic vascular and inflammatory condition rather than "just pain," and how to explain complex pathophysiology in patient-friendly language. The conversation covers essential screening guidelines for new adult patients, strategies for community providers managing sickle cell without specialist access, the evolving role of hydroxyurea (including the PIVOT trial in hemoglobin SC disease), and a practical, patient-centered approach to outpatient pain management.Clinical Pearls:The first visit is about trust, not just data. Understanding a patient's life context, not just their labs is foundational, especially for AYA patients re-entering care after a gap; overwhelming a new patient with testing can undermine that trust. Sickle cell disease is systemic, not just a localized vaso-occlusive crisis. Even "milder" genotypes like hemoglobin SC cause damage through chronic inflammation, hemolysis, and vascular interaction. The historical framing of SC as mild disease is outdated, and end-organ damage can appear early in young adults. Structured screening and collaboration close care gaps. New adult patients need a full baseline workup (CBC/retic, electrophoresis, renal and liver labs, brain MRI, ophthalmology referral), and providers without sickle cell specialization should identify a partner institution and use published NHLBI/ASH guidelines rather than navigating complex cases alone. Hydroxyurea remains foundational, even without perfect evidence in SC disease. It's the only FDA-approved therapy shown to prolong survival in sickle cell disease; while the PIVOT trial's data in hemoglobin SC disease is still limited, empiric use is reasonable in symptomatic patients showing signs of pain or end-organ damage. For additional ASH resources related to Sickle Cell Disease, please consider visiting our ASH Clinical Practice Guidelines on Sickle Cell Disease web page.This podcast episode is supported by Sanofi.
Immune thrombocytopenic purpura (ITP) is a diagnosis of exclusion but treating it is anything but straightforward. In this episode, Dr. Adam Cuker (University of Pennsylvania) joins us to break down how the management of ITP is evolving in real time, from diagnostic pitfalls to a preview of the newly released ASH ITP guidelines. We cover first-line corticosteroid strategies, when to add IVIG, how to choose between the many other available options in the second line and later settings. A world-expert in ITP management, Dr. Cuker shares many important clinical pearls and management strategies to help our listeners care for their patients with ITP. Clinical Pearls:1. ITP remains a diagnosis of exclusion with no confirmatory gold-standard test; diagnostic confidence is ultimately established by a robust platelet response to ITP-directed therapy (steroids, IVIG). Roughly two-thirds to three-quarters of adults with primary ITP will follow a chronic course, which should inform prognostic counseling at diagnosis. 2. Frontline management is evolving away from steroid monotherapy. While corticosteroids (prednisone or high-dose dexamethasone) remain the backbone, forthcoming ASH guideline updates support pairing steroids with a thrombopoietin receptor agonist (TPO-RA) or rituximab upfront rather than delaying combination therapy, given emerging evidence this approach may reduce steroid exposure and improve long-term disease course. 3. In the second-line setting, TPO-RAs (eltrombopag, avatrombopag, romiplostim) are generally favored over rituximab given higher overall response rates, though rituximab may be preferable in patients with high thrombotic risk, those averse to chronic medication, or young women with ITP of less than one year's duration, who show higher observed response rates. TPO-RA switching is well supported (i.e., failure of one agent does not preclude response to another). 4. Third-line options (fostamatinib, mycophenylate mofetil, rilzabrutinib), often combined with a TPO-RA to hit multiple mechanisms, are reserved for refractory disease; splenectomy is now reserved for highly refractory patients, those failing hospital-based salvage therapy, or patients with a strong preference to avoid chronic medication. For additional ASH resources related to ITP, please consider visiting our ASH Clinical Practice Guidelines on Immune Thrombocytopenia web page.This podcast episode is supported by Sanofi.







